AKT1 and breast cancer: In conclusion, our work suggests that ropivacaine functions as an AKT1-specific inhibitor, suppressing CSC-like phenotypes in breast cancer cells by inhibiting the NF-κB/GGT1 positive feedback loop (Fig. 11).